Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
USP11 siRNA
- Development stage
- Preclinical
- Lead developer
- RCSI University of Medicine and Health Sciences
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
USP11 siRNA is a small interfering RNA (siRNA) designed to target and knock down the expression of Ubiquitin Specific Peptidase 11 (USP11). USP11 is a deubiquitinating enzyme that has been implicated in various oncogenic pathways, particularly in stabilizing estrogen receptor alpha (ERα) and steroid receptor coactivator-3 (SRC-3/NCOA3) in estrogen receptor-positive (ER+) breast cancer. Knockdown of USP11 via siRNA has been shown to reduce cell proliferation, induce G2 cell cycle arrest and apoptosis, and abrogate ERα transcriptional activity in preclinical models. Delivery methods under investigation include encapsulation in the amphipathic cell-penetrating peptide RALA (developed in collaboration with pHion Therapeutics) and delivery via biocompatible freeze-dried collagen-based scaffolds.
- Other names
- siRNA targeting USP11siUSP11siUSP-11siUSP 11USP11 small interfering RNAUSP-11 small interfering RNAUSP 11 small interfering RNA
Beyond the preview
Go deeper on USP11 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on USP11 siRNA.